Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$272.64 USD
-4.69 (-1.69%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $272.59 -0.05 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Alnylam Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2,439 | 2,192 | 2,436 | 1,874 | 1,536 |
Receivables | 328 | 238 | 199 | 602 | 43 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 89 | 129 | 86 | 75 | 56 |
Other Current Assets | 126 | 133 | 88 | 63 | 80 |
Total Current Assets | 2,983 | 2,692 | 2,809 | 2,615 | 1,716 |
Net Property & Equipment | 526 | 523 | 502 | 465 | 425 |
Investments & Advances | 49 | 49 | 41 | 41 | 15 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 72 | 66 | 60 | 45 | 18 |
Total Assets | 3,830 | 3,546 | 3,643 | 3,407 | 2,395 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 56 | 98 | 73 | 52 | 50 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 713 | 545 | 395 | 356 | 197 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 158 | 82 | 187 | 141 | 78 |
Total Current Liabilities | 968 | 768 | 696 | 585 | 353 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 188 | 194 | 152 | 225 | 318 |
Convertible Debt | 1,021 | 1,017 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 676 | 191 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1,631 | 1,465 | 1,250 | 1,096 | 9 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 4,051 | 3,705 | 3,055 | 2,391 | 956 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 6,811 | 6,455 | 6,058 | 5,644 | 5,201 |
Retained Earnings | -7,010 | -6,569 | -5,438 | -4,585 | -3,727 |
Other Equity | -23 | -45 | -33 | -44 | -37 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -221 | -158 | 588 | 1,016 | 1,439 |
Total Liabilities & Shareholder's Equity | 3,830 | 3,546 | 3,643 | 3,407 | 2,395 |
Total Common Equity | -221 | -158 | 588 | 1,016 | 1,439 |
Shares Outstanding | 125.40 | 123.00 | 119.60 | 116.10 | 111.40 |
Book Value Per Share | -1.76 | -1.29 | 4.92 | 8.75 | 12.91 |
Fiscal Year End for Alnylam Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2,625 | 2,371 | 2,439 | 2,406 | 2,058 |
Receivables | 309 | 321 | 328 | 325 | 221 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 84 | 94 | 89 | 96 | 100 |
Other Current Assets | 155 | 202 | 126 | 158 | 145 |
Total Current Assets | 3,173 | 2,989 | 2,983 | 2,985 | 2,524 |
Net Property & Equipment | 517 | 523 | 526 | 526 | 527 |
Investments & Advances | 49 | 49 | 49 | 49 | 49 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 72 | 67 | 72 | 75 | 93 |
Total Assets | 4,010 | 3,824 | 3,830 | 3,839 | 3,402 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 74 | 78 | 56 | 74 | 60 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 809 | 699 | 713 | 713 | 599 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 131 | 123 | 158 | 121 | 88 |
Total Current Liabilities | 1,055 | 942 | 968 | 950 | 789 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 2 | 186 | 188 | 196 | 194 |
Convertible Debt | 1,023 | 1,022 | 1,021 | 1,020 | 1,019 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1,693 | 1,631 | 1,592 | 1,556 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 4,013 | 4,044 | 4,051 | 4,005 | 3,811 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 7,123 | 6,882 | 6,811 | 6,737 | 6,647 |
Retained Earnings | -7,092 | -7,076 | -7,010 | -6,872 | -7,019 |
Other Equity | -35 | -27 | -23 | -32 | -37 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -3 | -219 | -221 | -166 | -408 |
Total Liabilities & Shareholder's Equity | 4,010 | 3,824 | 3,830 | 3,839 | 3,402 |
Total Common Equity | -3 | -219 | -221 | -166 | -408 |
Shares Outstanding | 128.30 | 126.40 | 125.40 | 125.40 | 125.00 |
Book Value Per Share | -0.02 | -1.73 | -1.76 | -1.32 | -3.27 |